Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea · Delayed Price · Currency is KRW 452,000
+1,000 (0.22%)
Dec 30, 2025, 3:30 PM KST
Hanmi Pharm. Revenue
Hanmi Pharm. had revenue of 362.35B KRW in the quarter ending September 30, 2025, with 0.07% growth. This brings the company's revenue in the last twelve months to 1.47T, down -6.39% year-over-year. In the year 2024, Hanmi Pharm. had annual revenue of 1.50T with 0.31% growth.
Revenue (ttm)
1.47T
Revenue Growth
-6.39%
P/S Ratio
3.91
Revenue / Employee
610.91M
Employees
2,400
Market Cap
5.73T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.50T | 4.61B | 0.31% |
| Dec 31, 2023 | 1.49T | 159.34B | 11.97% |
| Dec 31, 2022 | 1.33T | 128.36B | 10.67% |
| Dec 31, 2021 | 1.20T | 127.33B | 11.84% |
| Dec 31, 2020 | 1.08T | -37.80B | -3.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| ABL Bio | 88.44B |
Hanmi Pharm. News
- 5 weeks ago - Aptose Biosciences agrees to be acquired by Hanmi Pharmaceutical subsidiary for C$2.41 per share - Seeking Alpha